Patrys [ASX: PAB]
Pharmaceuticals & Biotechnology
A De-Risked Clinical Opportunity with Multiple Near-Term Catalysts in the Growing Delirium Market
We initiate coverage on Patrys Ltd (ASX: PAB) with a target price of $0.13, implying a 205% upside from the current share price of $0.04. Patrys is an emerging clinical-stage pharmaceutical and biotechnology company whose investment case has been materially reshaped by the acquisition of Reliis Pty Ltd and its proprietary injectable reformulation of the quetiapine program for delirium. The addition of this asset provides Patrys with a near-term clinical and regulatory opportunity alongside its legacy biologics platform, broadening the company’s pipeline and improving its overall risk-reward profile.
Attractive Exposure to a Large and Underserved Critical Care Market
Patrys provides exposure to a differentiated late-preclinical hospital-based Central Nervous System (CNS) opportunity targeting delirium, a common and costly condition affecting millions of patients annually. Delirium occurs in up to 80% of ICU patients and is associated with prolonged hospital stays, increased mortality, long-term cognitive decline and an estimated annual economic burden of US$38-152 billion in the United States alone. Despite its prevalence, treatment options remain limited, with clinicians relying largely on supportive care and off-label oral antipsychotics. RLS-2202, a proprietary injectable formulation of quetiapine, is specifically designed for critically ill patients who are intubated, sedated or unable to swallow, addressing a significant unmet need in acute care settings.
Importantly, RLS-2202 is being developed via the Food and Drug Administration (FDA) 505(b)(2) pathway, leveraging the extensive clinical experience and established safety profile of quetiapine while creating value through formulation and delivery innovation. This de-risked development strategy has previously supported significant value creation in hospital-focused reformulation products, including Ofirmev® and Nexterone®, which were acquired in transactions valued at US$1.3 billion and US$338 million, respectively. We believe RLS-2202 shares many of the same characteristics that made these products attractive acquisition targets, including improved hospital workflow, enhanced ease of use and the potential to address a substantial unmet clinical need.
De-risking Pathway Through Credible Partnerships
Patrys has significantly de-risked its path to clinic through partnerships with specialist providers across manufacturing, regulatory and clinical execution. BioCina is supporting sterile injectable manufacturing and Chemistry, Manufacturing, and Controls (CMC) development; Facet Life Sciences is advising on FDA strategy; Alithia Life Sciences provides Contract Research Organisation (CRO) oversight; and CMAX offers established Phase 1 trial infrastructure. Together, these partnerships enhance execution certainty, reduce development risk and provide a capital-efficient pathway into the clinic.
Valuation
We derive a base case target price of $0.11, implying 160% upside to the current share price of $0.04, while our upside case supports a target price of $0.15, representing a more substantial 250% upside potential, resulting in a midpoint Price/NAV of 0.33x. Our valuation framework remains deliberately conservative, as it attributes value only to the probability-weighted opportunity for Patrys’s proprietary injectable quetiapine program within the US ICU setting, with no incremental contribution from broader delirium settings, ex-US markets or the company’s legacy biologics platform. In our view, this leaves scope for meaningful upside beyond the model as Patrys advances RLS-2202 through manufacturing, regulatory and clinical milestones over the next 12-24 months, with each step toward first-in-human IV dosing, Phase 1 completion and regulatory engagement having the potential to further de-risk the asset and support a progressive market re-rating.